• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

成人原发性免疫性血小板减少症中国治疗指南。

Chinese guidelines for treatment of adult primary immune thrombocytopenia.

作者信息

Liu Xin-Guang, Bai Xiao-Chuan, Chen Fang-Ping, Cheng Yun-Feng, Dai Ke-Sheng, Fang Mei-Yun, Feng Jian-Ming, Gong Yu-Ping, Guo Tao, Guo Xin-Hong, Han Yue, Hong Luo-Jia, Hu Yu, Hua Bao-Lai, Huang Rui-Bing, Li Yan, Peng Jun, Shu Mi-Mi, Sun Jing, Sun Pei-Yan, Sun Yu-Qian, Wang Chun-Sen, Wang Shu-Jie, Wang Xiao-Min, Wu Cong-Ming, Wu Wen-Man, Yan Zhen-Yu, Yang Feng-E, Yang Lin-Hua, Yang Ren-Chi, Yang Tong-Hua, Ye Xu, Zhang Guang-Sen, Zhang Lei, Zheng Chang-Cheng, Zhou Hu, Zhou Min, Zhou Rong-Fu, Zhou Ze-Ping, Zhu Hong-Li, Zhu Tie-Nan, Hou Ming

机构信息

Department of Hematology, Qilu Hospital, Shandong University, Jinan, 250012, China.

General Hospital of Ningxia Medical University, Yinchuan, China.

出版信息

Int J Hematol. 2018 Jun;107(6):615-623. doi: 10.1007/s12185-018-2445-z. Epub 2018 Apr 4.

DOI:10.1007/s12185-018-2445-z
PMID:29619624
Abstract

Primary immune thrombocytopenia (ITP) is a bleeding disorder commonly encountered in clinical practice. The International Working Group (IWG) on ITP has published several landmark papers on terminology, definitions, outcome criteria, bleeding assessment, diagnosis, and management of ITP. The Chinese consensus reports for diagnosis and management of adult ITP have been updated to the 4th edition. Based on current consensus positions and new emerging clinical evidence, the thrombosis and hemostasis group of the Chinese Society of Hematology issued Chinese guidelines for management of adult ITP, which aim to provide evidence-based recommendations for clinical decision making.

摘要

原发性免疫性血小板减少症(ITP)是临床实践中常见的出血性疾病。国际ITP工作组(IWG)发表了多篇关于ITP的术语、定义、疗效标准、出血评估、诊断和管理的里程碑式论文。成人ITP诊断和管理的中国专家共识报告已更新至第4版。基于当前的共识立场和新出现的临床证据,中华医学会血液学分会血栓与止血学组发布了成人ITP管理中国指南,旨在为临床决策提供循证推荐。

相似文献

1
Chinese guidelines for treatment of adult primary immune thrombocytopenia.成人原发性免疫性血小板减少症中国治疗指南。
Int J Hematol. 2018 Jun;107(6):615-623. doi: 10.1007/s12185-018-2445-z. Epub 2018 Apr 4.
2
Evidence-based management of immune thrombocytopenia: ASH guideline update.基于证据的免疫性血小板减少症管理:ASH 指南更新。
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):568-575. doi: 10.1182/asheducation-2018.1.568.
3
Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group.免疫性血小板减少症出血评估的标准化:国际工作组报告。
Blood. 2013 Apr 4;121(14):2596-606. doi: 10.1182/blood-2012-07-442392. Epub 2013 Jan 29.
4
Applicability of 2009 international consensus terminology and criteria for immune thrombocytopenia to a clinical pediatric population.2009 年国际免疫性血小板减少症共识术语和标准在临床儿科人群中的适用性。
Pediatr Blood Cancer. 2012 Feb;58(2):216-20. doi: 10.1002/pbc.23112. Epub 2011 Jun 14.
5
Conflicts of interest and clinical recommendations: comparison of two concurrent clinical practice guidelines for primary immune thrombocytopenia developed by different methods.利益冲突与临床建议:不同方法制定的两份原发性免疫性血小板减少症并行临床实践指南的比较
Am J Med Qual. 2014 Jan-Feb;29(1):53-60. doi: 10.1177/1062860613481618. Epub 2013 Apr 2.
6
The 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia.2022 年对 2019 年美国血液学会免疫性血小板减少症指南的回顾。
Blood Adv. 2024 Jul 9;8(13):3578-3582. doi: 10.1182/bloodadvances.2023012541.
7
Diagnosis and treatment of idiopathic thrombocytopenic purpura: recommendations of the American Society of Hematology. The American Society of Hematology ITP Practice Guideline Panel.特发性血小板减少性紫癜的诊断与治疗:美国血液学会的建议。美国血液学会特发性血小板减少性紫癜实践指南小组。
Ann Intern Med. 1997 Feb 15;126(4):319-26. doi: 10.7326/0003-4819-126-4-199702150-00010.
8
Immune thrombocytopenic purpura in pregnancy.妊娠期免疫性血小板减少性紫癜
Curr Opin Hematol. 2007 Sep;14(5):574-80. doi: 10.1097/MOH.0b013e3282bf6dc2.
9
[Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)].[成人原发性免疫性血小板减少症:奥地利血液学和肿瘤学会(ÖGHO)诊断与治疗共识声明]
Wien Klin Wochenschr. 2012 Feb;124(3-4):111-23. doi: 10.1007/s00508-012-0123-3. Epub 2012 Mar 3.
10
Diagnosis and classification of immune-mediated thrombocytopenia.免疫介导性血小板减少症的诊断与分类。
Autoimmun Rev. 2014 Apr-May;13(4-5):577-83. doi: 10.1016/j.autrev.2014.01.026. Epub 2014 Jan 18.

引用本文的文献

1
Real-world experience of hetrombopag in immune thrombocytopenia treatment: a retrospective cohort study.艾曲泊帕治疗免疫性血小板减少症的真实世界经验:一项回顾性队列研究。
Eur J Med Res. 2025 Jul 5;30(1):574. doi: 10.1186/s40001-025-02850-7.
2
Comparative efficacy and safety of rhTPO, romiplostim, and eltrombopag in the treatment of pediatric primary immune thrombocytopenia: a systematic review and network meta-analysis.重组人血小板生成素、罗米司亭和艾曲泊帕治疗儿童原发性免疫性血小板减少症的疗效与安全性比较:一项系统评价和网状Meta分析
Front Immunol. 2025 Jun 6;16:1595774. doi: 10.3389/fimmu.2025.1595774. eCollection 2025.
3

本文引用的文献

1
[Comparative study between two bleeding grading systems of primary immune thrombocytopenia].[原发性免疫性血小板减少症两种出血分级系统的比较研究]
Zhonghua Xue Ye Xue Za Zhi. 2017 May 14;38(5):394-398. doi: 10.3760/cma.j.issn.0253-2727.2017.05.008.
2
[Chinese expert consensus on the diagnosis and treatment of aplastic anemia (2017)].再生障碍性贫血诊断与治疗中国专家共识(2017年版)
Zhonghua Xue Ye Xue Za Zhi. 2017 Jan 14;38(1):1-5. doi: 10.3760/cma.j.issn.0253-2727.2017.01.001.
3
Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia.
Dynamic changes in platelet counts and psychological state in ITP patients after COVID-19 infection.
COVID-19感染后ITP患者血小板计数及心理状态的动态变化
Front Med (Lausanne). 2025 Mar 14;12:1485418. doi: 10.3389/fmed.2025.1485418. eCollection 2025.
4
Challenges in treating primary immune thrombocytopenia patients undergoing COVID-19 vaccination: A retrospective study.新冠病毒疫苗接种的原发性免疫性血小板减少症患者的治疗挑战:一项回顾性研究。
Open Med (Wars). 2024 Mar 23;19(1):20240928. doi: 10.1515/med-2024-0928. eCollection 2024.
5
Combination of two target agonists of the thrombopoietin and thrombopoietin receptor in the treatment of elderly patients with refractory immune thrombocytopenia.血小板生成素和血小板生成素受体的两种靶向激动剂联合用于治疗老年难治性免疫性血小板减少症患者。
Cancer Pathog Ther. 2022 Oct 17;1(2):154-156. doi: 10.1016/j.cpt.2022.09.005. eCollection 2023 Apr.
6
Decreased Expression of IL-35 and Its Receptor Contributes to Impaired Megakaryopoiesis in the Pathogenesis of Immune Thrombocytopenia.IL-35 及其受体表达降低导致免疫性血小板减少症发病机制中的巨核细胞生成受损。
Adv Sci (Weinh). 2024 Mar;11(12):e2305798. doi: 10.1002/advs.202305798. Epub 2024 Jan 15.
7
Therapeutic Outcomes of High Dose-Dexamethasone versus Prednisolone + Azathioprine, Rituximab, Eltrombopag, and Romiplostim Strategies in Persistent, Chronic, Refractory, and Relapsed Immune Thrombocytopenia Patients.高剂量地塞米松与泼尼松龙+硫唑嘌呤、利妥昔单抗、艾曲泊帕和罗米司亭治疗持续性、慢性、难治性和复发性免疫性血小板减少症患者的疗效比较
Pharmaceuticals (Basel). 2023 Aug 29;16(9):1215. doi: 10.3390/ph16091215.
8
The association between platelet glycoprotein-specific antibodies and response to short-term high-dose dexamethasone with prednisone maintenance treatment in adult patients with primary immune thrombocytopenia.血小板糖蛋白特异性抗体与成人原发免疫性血小板减少症患者短期大剂量地塞米松联合泼尼松维持治疗反应的相关性。
Ann Med. 2022 Dec;54(1):132-137. doi: 10.1080/07853890.2021.2018486.
9
How we treat primary immune thrombocytopenia in adults.成人原发免疫性血小板减少症的治疗方法。
J Hematol Oncol. 2023 Jan 19;16(1):4. doi: 10.1186/s13045-023-01401-z.
10
Recombinant Thrombopoietin Effectively Shortens the Time to Response and Increases Platelet Counts in Elderly Patients with Severe Immune Thrombocytopenia.重组血小板生成素有效缩短老年重症免疫性血小板减少症患者的起效时间并提高血小板计数。
J Clin Med. 2022 Sep 29;11(19):5763. doi: 10.3390/jcm11195763.
艾曲泊帕在中国慢性免疫性血小板减少症患者中疗效与安全性的多中心、随机、III期研究
Br J Haematol. 2017 Jan;176(1):101-110. doi: 10.1111/bjh.14380. Epub 2016 Oct 13.
4
Tolerability and Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia: Meta-Analysis of Randomized Controlled Trials.艾曲泊帕在慢性免疫性血小板减少症中的耐受性和疗效:随机对照试验的荟萃分析
Clin Appl Thromb Hemost. 2017 Nov;23(8):928-937. doi: 10.1177/1076029616663849. Epub 2016 Aug 29.
5
A Randomized Trial of Daily Prednisone versus Pulsed Dexamethasone in Treatment-Naïve Adult Patients with Immune Thrombocytopenia: EIS 2002 Study.初治免疫性血小板减少症成年患者每日服用泼尼松与脉冲式地塞米松治疗的随机试验:EIS 2002研究
Acta Haematol. 2016;136(2):101-7. doi: 10.1159/000445420. Epub 2016 May 19.
6
[Clinical Analysis of Recombinant Human Thrombopoietin for Treatment of 46 Adult Patients with Newly Diagnosed Primary Immune Thrombocytopenia].重组人血小板生成素治疗46例新诊断成人原发性免疫性血小板减少症的临床分析
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Apr;24(2):531-5. doi: 10.7534/j.issn.1009-2137.2016.02.042.
7
[Consensus of Chinese experts on diagnosis and treatment of adult primary immune thrombocytopenia (version 2016)].《成人原发性免疫性血小板减少症诊断与治疗中国专家共识(2016年版)》
Zhonghua Xue Ye Xue Za Zhi. 2016 Feb;37(2):89-93. doi: 10.3760/cma.j.issn.0253-2727.2016.02.001.
8
Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.艾曲泊帕在临床实践中用于原发性慢性免疫性血小板减少症的安全性和有效性。
Eur J Haematol. 2016 Sep;97(3):297-302. doi: 10.1111/ejh.12725. Epub 2016 Jan 27.
9
The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).血小板生成素受体激动剂(TPO-RAs)在免疫性血小板减少症(ITP)中的应用:普利亚血液学网络(REP)的一项“真实生活”回顾性多中心经验。
Ann Hematol. 2016 Jan;95(2):239-44. doi: 10.1007/s00277-015-2556-z. Epub 2015 Nov 24.
10
High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial.大剂量地塞米松与泼尼松治疗成人免疫性血小板减少症:一项前瞻性多中心随机试验。
Blood. 2016 Jan 21;127(3):296-302; quiz 370. doi: 10.1182/blood-2015-07-659656. Epub 2015 Oct 19.